Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Change in Accured Expenses (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Change in Accured Expenses for 16 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 34.92% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2025, down 57.69% year-over-year, with the annual reading at $5.9 million for FY2025, 57.69% down from the prior year.
  • Change in Accured Expenses hit $7.3 million in Q4 2025 for Ligand Pharmaceuticals, up from $1.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $11.3 million in Q4 2024 to a low of -$4.8 million in Q2 2021.
  • Historically, Change in Accured Expenses has averaged $727550.0 across 5 years, with a median of $31500.0 in 2021.
  • Biggest five-year swings in Change in Accured Expenses: surged 840.0% in 2021 and later tumbled 676.17% in 2022.
  • Year by year, Change in Accured Expenses stood at $6.4 million in 2021, then tumbled by 145.54% to -$2.9 million in 2022, then skyrocketed by 193.94% to $2.8 million in 2023, then surged by 309.36% to $11.3 million in 2024, then crashed by 34.92% to $7.3 million in 2025.
  • Business Quant data shows Change in Accured Expenses for LGNDZ at $7.3 million in Q4 2025, $1.1 million in Q3 2025, and -$407000.0 in Q2 2025.